CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity Of AUTO3, a CAR T Cell Treatment Targeting CD19 And CD22 in Paediatric And Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Sponsor: Autolus Limited
This PHASE1/PHASE2 trial investigates B Acute Lymphoblastic Leukemia and B-cell Acute Lymphoblastic Leukemia and is currently completed. Autolus Limited leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Mar 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2018 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Autolus Limited
For direct contact, visit the study record on ClinicalTrials.gov .